Literature DB >> 9016914

D-cycloserine, a glycine site agonist, reverses working memory failure by hippocampal muscarinic receptor blockade in rats.

M Ohno1, S Watanabe.   

Abstract

D-Cycloserine, a partial agonist at the glycine binding site on the NMDA receptor/channel complex, did not affect the number of errors (attempts to pass through two incorrect panels of the three-panel gates at four choice points) in the working memory task with a three-panel runway setup, when injected bilaterally at 1 or 10 microg/side into the dorsal hippocampus. Intrahippocampal administration of the muscarinic receptor antagonist scopolamine (3.2 microg/side) significantly increased the number of working memory errors. The increase in working memory errors induced by intrahippocampal 3.2 microg/side scopolamine was significantly reduced by concurrent infusion of 1 and 10 microg/side D-cycloserine. These results suggest that positive modulation of the NMDA receptor/channel through activation of the glycine site can compensate dysfunction of hippocampal cholinergic neurotransmission involved in working memory function.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9016914     DOI: 10.1016/s0014-2999(96)00907-7

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  10 in total

1.  Dissociating scopolamine-induced disrupted and persistent latent inhibition: stage-dependent effects of glycine and physostigmine.

Authors:  Segev Barak; Ina Weiner
Journal:  Psychopharmacology (Berl)       Date:  2010-02-24       Impact factor: 4.530

2.  Randomized controlled trial of d-cycloserine in cocaine dependence: Effects on contingency management and cue-induced cocaine craving in a naturalistic setting.

Authors:  Matthew W Johnson; Natalie R Bruner; Patrick S Johnson; Kenneth Silverman; Meredith S Berry
Journal:  Exp Clin Psychopharmacol       Date:  2019-08-01       Impact factor: 3.157

3.  Intra-hippocampal D-cycloserine rescues decreased social memory, spatial learning reversal, and synaptophysin levels in aged rats.

Authors:  Marta Portero-Tresserra; Margarita Martí-Nicolovius; Mireia Tarrés-Gatius; Ana Candalija; Gemma Guillazo-Blanch; Anna Vale-Martínez
Journal:  Psychopharmacology (Berl)       Date:  2018-02-28       Impact factor: 4.530

4.  d-cycloserine reverses the detrimental effects of stress on learning in females and enhances retention in males.

Authors:  Jaylyn Waddell; Elyse Mallimo; Tracey Shors
Journal:  Neurobiol Learn Mem       Date:  2009-08-08       Impact factor: 2.877

5.  Neuroprotective effect of gadolinium: a stretch-activated calcium channel blocker in mouse model of ischemia-reperfusion injury.

Authors:  Puja Gulati; Arunachalam Muthuraman; Amteshwar S Jaggi; Nirmal Singh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-12-11       Impact factor: 3.000

Review 6.  NMDA receptors and fear extinction: implications for cognitive behavioral therapy.

Authors:  Michael Davis
Journal:  Dialogues Clin Neurosci       Date:  2011       Impact factor: 5.986

7.  Scopolamine administration modulates muscarinic, nicotinic and NMDA receptor systems.

Authors:  Soheil Keihan Falsafi; Alev Deli; Harald Höger; Arnold Pollak; Gert Lubec
Journal:  PLoS One       Date:  2012-02-23       Impact factor: 3.240

8.  NMDA receptor modulation by D-cycloserine promotes episodic-like memory in mice.

Authors:  Armin Zlomuzica; Maria A De Souza Silva; Joseph P Huston; Ekrem Dere
Journal:  Psychopharmacology (Berl)       Date:  2007-05-12       Impact factor: 4.415

Review 9.  NMDA Receptor Function During Senescence: Implication on Cognitive Performance.

Authors:  Ashok Kumar
Journal:  Front Neurosci       Date:  2015-12-16       Impact factor: 4.677

10.  D-cycloserine in prelimbic cortex reverses scopolamine-induced deficits in olfactory memory in rats.

Authors:  Marta Portero-Tresserra; Paula Cristóbal-Narváez; Margarita Martí-Nicolovius; Gemma Guillazo-Blanch; Anna Vale-Martínez
Journal:  PLoS One       Date:  2013-08-02       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.